New analysis links teclistamab combination to longer survival in relapsed myeloma
An adjusted comparison across three trials found better outcomes than two daratumumab-based combinations, but it was not a direct randomized comparison.
Moderate evidenceHuman studyInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
The analysis included patients whose multiple myeloma had returned or no longer responded to treatment after one to three previous lines of therapy. Researchers used a statistical method called inverse probability of treatment weighting to make the groups more similar in measured baseline characteristics. They compared teclistamab plus daratumumab with daratumumab plus carfilzomib and dexamethasone, and with daratumumab plus bortezomib and dexamethasone.
After adjustment, the teclistamab combination was associated with longer progression-free survival and overall survival than both comparison regimens. It was also associated with higher rates of overall response and deeper responses. These results add comparative information, but the findings remain subject to the limits of comparing participants from different trials rather than assigning all participants to treatments within one trial.
What the study looked at
Researchers examined whether teclistamab plus daratumumab was associated with better outcomes than two proteasome-inhibitor-based regimens in people with relapsed or refractory multiple myeloma after one to three prior lines of treatment. They used individual patient data from the phase 3 MajesTEC-3 trial for the teclistamab combination, the CANDOR trial for daratumumab plus carfilzomib and dexamethasone, and the CASTOR trial for daratumumab plus bortezomib and dexamethasone. Inverse probability of treatment weighting was used to adjust for measured differences in patient characteristics between the trial populations. Outcomes included progression-free survival, overall survival, overall response, very good partial response or better, and complete response or better. The abstract does not state the number of patients in the teclistamab group or the total number analyzed across all comparisons.
What the analysis found
After statistical adjustment, teclistamab plus daratumumab was associated with longer progression-free survival than daratumumab plus carfilzomib and dexamethasone, with a hazard ratio of 0.22, and than daratumumab plus bortezomib and dexamethasone, with a hazard ratio of 0.11. It was also associated with longer overall survival, with hazard ratios of 0.40 and 0.24, respectively. A hazard ratio below 1 indicates fewer observed events in the teclistamab comparison group, but it does not by itself prove that the treatment caused the difference.
The reported relative rates of overall response, very good partial response or better, and complete response or better were higher with teclistamab plus daratumumab than with the carfilzomib-based regimen: 1.11, 1.33, and 2.84, respectively. The corresponding relative rates compared with the bortezomib-based regimen were 1.10, 2.20, and 5.17. The abstract reports statistically significant survival comparisons, but it does not provide the actual median survival times, follow-up duration, or detailed safety results.
Where this may apply
These findings may be most relevant to adults with relapsed or refractory multiple myeloma who are similar to participants treated after one to three prior lines of therapy in the included trials. They do not directly establish outcomes for people with newly diagnosed multiple myeloma, substantially different prior treatment histories, different health conditions, or patients not represented in those trials. The results also do not show which regimen is suitable for any individual person, and they should not be assumed to apply to other cancers or treatment settings.
The significance
For people with multiple myeloma that has returned or stopped responding after one to three prior treatments, the analysis provides indirect evidence that the teclistamab and daratumumab combination may be associated with longer disease control, survival, and deeper tumor responses than the two studied comparison regimens. It may help researchers compare treatment results when direct head-to-head trial data are unavailable. The findings do not establish that the combination is appropriate for every patient, and they do not replace evidence from a direct randomized comparison.
Limitations & evidence assessment
The main limitation is that this was an indirect comparison of participants from separate trials, not a single trial that randomly assigned patients to all three treatment strategies. Statistical weighting can adjust only for measured and available differences; unmeasured differences in patients, care, eligibility rules, follow-up, or trial procedures could have affected the results. In the original MajesTEC-3 comparison, most patients in the standard-care group received an immunomodulatory-drug-based regimen rather than a proteasome-inhibitor-based regimen, while this analysis used data from other trials to examine the proteasome-inhibitor comparisons. The abstract provides limited information about total sample sizes, follow-up duration, adverse effects, and missing data, so those aspects cannot be assessed here.
Why this evidence level: Clinical trial without confirmed randomization details in the available metadata.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Advances in Therapy · 2026 · DOI: 10.1007/s12325-026-03832-9
This systematic review and meta-analysis examined whether ultra-low-dose computed tomography (CT) can detect pulmonary, or lung, nodules while using less radiation than standard-dose CT. Across 42 studies involving 15,792 patients, pooled sensitivity for nodule detection was 91.9%, but results varied greatly between studies. The review also found that ultra-low-dose CT used an average effective dose of 0.22 millisieverts (mSv), while detection was less reliable for some small or hazy nodules and in patients with a high body mass index.
In an online randomized experiment involving 3,519 Chilean parents, researchers tested whether adding an “ULTRAPROCESSED” warning to Chile’s existing nutrient labels changed views of potato chips. The added label improved identification of ultraprocessed products and lowered reported purchase intentions and perceived healthfulness, but the effects were smaller when products already had more nutrient warnings. The study measured stated responses, not actual purchases or health outcomes.
A systematic review and network meta-analysis examined nonhormonal prescription medicines for hot flashes and related symptoms among adult women with breast cancer or a history of breast cancer. Across 19 study or substudy records involving 2,224 participants, five medicines showed statistically greater symptom improvement than placebo, but the evidence for comparing safety between medicines was limited.
